Four-drug regimens, such as FIr-B/FOx schedule, can improve efficacy of first-line treatment of metastatic colorectal cancer (MCRC) patients. The present study specifically evaluates feasibility of FIr-B/FOx first-line intensive regimen in fit young-elderly MCRC patients, representing approximately 40% of overall MCRC patients. Activity, efficacy, and safety were equivalent to overall MCRC patients, not significantly different according to KRAS genotype. Clinical outcome was significantly prolonged in liverlimited compared to other/multiple metastatic disease. Safety evaluation of the individual young-elderly patient showed that limiting toxicity syndromes (LTS) in multiple sites were significantly increased, compared to LTS in single site, with respect to non-elderly patients.
Introduction
Clinical management of MCRC is faced with different options and lines of treatment according to patients' fitness, extension of metastatic disease, and KRAS genotype [1] [2] [3] [4] [5] [6] . First line triplet regimens of chemotherapeutic drugs, or doublet associated to bevacizumab (BEV) or cetuximab, reported in phase III trials objective response rate (ORR) 39%-68%, progression-free survival (PFS) 7.2-10.6 months, and overall survival (OS) 19.9-26.1 months [2, 4, [6] [7] [8] . More intensive triplet chemotherapy plus targeted agents can further achieve ORR 82%, liver metastasectomies 26%, PFS 12 months, OS 28 months [1] [2] [3] [4] [5] . In liver-limited (L-L) disease, metastasectomies were 54%, and clinical outcome was significantly improved, particularly in KRAS wild-type patients [3, 5] .
Older patients are usually underrepresented in clinical trials, despite the increased incidence with age, and often undertreated in clinical practice. Retrospective studies showed similar safety and efficacy in fit elderly compared to younger patients [9] [10] [11] . Elderly patients require a decisionmaking process including functional, nutritional, and comorbidity status to discriminate fitness and tailor medical treatment [12] . Fit patients ≥70 years benefit from 5-fluorouracil (5-FU) as younger patients: ORR 23.9%, PFS 5.5 months, and OS 10.8 months [13] . A retrospective review and a pooled analysis reported no different activity and efficacy [14, 15] . The same benefit was reported from irinotecan (CPT-11) containing chemotherapy in fit older ≥70 years [16] ; age was not an independent prognostic factor for OS [17] . The significantly improved relative benefit of FOLFOX did not differ by age [18] . In the OPTIMOX1 trial, ORR 59%, median PFS 9.0 months, and median OS 20.7 months were comparable in old-elderly patients [19] . In the FOCUS2 trial, specifically designed to evaluate first line reduced-dose (80%) of 5-FU or capecitabine with or without oxaliplatin (OXP), in old-elderly and/or frail patients, addition of OXP significantly improved ORR, and trendly PFS, but not OS [20] . Treatment efficacy was consistent across subgroups, 2 BioMed Research International including age, when BEV was combined with CPT-11-based therapy [21] . In fit elderly patients, addition of BEV to 5-FU based chemotherapy significantly prolonged PFS (9.2-9.3 months) and OS (17.4-19 .3 months) [22, 23] . In BRiTE and BEAT studies, no different PFS was observed; median OS decreased with age [24, 25] . No impact on PFS and OS was observed by age and/or comorbidities in patients treated with FOLFOX or FOLFIRI added or not to cetuximab [26] . Addition of panitumumab to FOLFOX showed no clear benefit in PFS in elderly and performance status 2 patients [27] .
In the randomized phase III trial comparing FOLFOXIRI with FOLFIRI, age was not a significant factor for activity and efficacy; elderly patients showed median OS 16.9 and 19.9 months with FOLFIRI or FOLFOXIRI, respectively [28, 29] . ORR was significantly lower in older patients treated with FOLFOXIRI [29] ; no differences were reported in PFS and OS. Patients underwent metastasectomies without increased morbidity or mortality, irrespective of age.
Here, we report a retrospective analysis evaluating activity, efficacy, and safety of first-line FIr-B/FOx intensive regimen and the prognostic value of extension of metastatic disease [4, 5] in fit young-elderly MCRC patients enrolled in a previously reported phase II study [1] and in the expanded clinical program proposing first-line FIr-B/FOx treatment.
Materials and Methods

Patient Eligibility.
Present retrospective analysis evaluated consecutive young-elderly patients 65 to 75 years enrolled in a previously reported phase II study [1] and in the expanded clinical program proposing first-line FIr-B/FOx treatment. Patients who were eligible were with histologically confirmed diagnosis of measurable MCRC, performance status ≤2, adequate hematological, renal, and hepatic functions, and life expectancy >3 months. Patients were not eligible if they showed uncontrolled severe diseases; cardiovascular disease (uncontrolled hypertension, uncontrolled arrhythmia, and ischemic cardiac diseases in the last year); thromboembolic disease, coagulopathy, and preexisting bleeding diatheses; proteinuria >1 g/24 h urine; surgery within the previous 28 days before. Cumulative Index Rating Scale (CIRS) was used to evaluate the comorbidity status, and only patients with primary and intermediate CIRS stage were enrolled [12] . 
Study Design.
Response was evaluated by computed tomography scan; positron emission tomography was added based on investigators' assessment. Follow-up was scheduled every three months up to progression or death. Resectability, defined according to reported categories [3] , was evaluated in patients with L-L metastases every three cycles by a multidisciplinary team, consisting of a medical oncologist, liver surgeon, and radiologist, and recommended >4 weeks after BEV discontinuation. Liver metastasectomies were defined as R0, if radical surgery, R1, if radioablation was added. Toxicity was registered according to the National Cancer Institute Common Toxicity Criteria (version 3.0). Limiting toxicity (LT) was defined as grade 3-4 non-hematological toxicity, grade 4 hematologic toxicity, febrile neutropenia, or any toxicity determining >2 weeks treatment delay. To discriminate individual safety, limiting toxicity syndromes (LTS), consisting of at least an LT associated or not to other limiting or G2 toxicities, were evaluated, as previously reported [1] . LTS were classified as limiting toxicity syndromes single site (LTS-ss), characterized only by the LT, and limiting toxicity syndromes multiple sites (LTS-ms), ≥2 LTs or an LT associated to other, at least G2, non-limiting toxicities. Chi-square test was used to compared the rates of LTS-ms and LTS-ss [34] .
Clinical criteria of activity and efficacy were ORR, PFS and OS. ORR was evaluated according to RECIST criteria [35] ; pathologic complete response was defined as absence of residual cancer cells in surgically resected specimens. PFS capecitabine, 1 (6%); surgery, 1 (6%). Most KRAS wildtype patients received a second line anti-EGFR-containing treatment (7 out of 9, 78%); BEV-containing, 1 (11%); surgery, 1 (11%). Seven patients (25%) received a third line treatment: cetuximab-containing treatment, 2 (28.5%); panitumumab, 3 (43%); capecitabine, 2 (28.5%). Three patients (11%) received a fourth line treatment: CPT-11, 1 (33%); raltitrexed, 1 (33%); capecitabine, 1 (33%). Three patients (11%) received treatment beyond the fourth line: fifth line cetuximab-containing treatment, 1 (33%), raltitrexed, 1 (33%); sixth line capecitabine, 1 (33%). Among 13 KRAS wild-type patients, ORR was 92% ( 0.05, CI ± 15) ( Table 2) . We observed 12 objective responses: 10 partial (77%) and 2 CR (15%) and 1 progressive disease (8%). Liver metastasectomies were performed in 3 patients (23%), 2 out of 4 L-L (50%). Median PFS was 14 months (4-78+ months). Median OS was 38 months (8-78+ months). Among the 9 KRAS/BRAF wild-type patients, ORR was 89% ( 0.05, CI ± 22), median PFS was 11 months (4-49+ months), and median OS was 23 months (8-59 months). Among 13 KRAS mutant patients, ORR was 77% ( 0.05, CI ± 24). We observed 10 objective responses: 9 partial (69%) and 1 CR (8%), 1 stable (8%), and 2 progressive diseases (15%). Disease control rate was 85% ( 0.05, CI ± 20). Liver metastasectomies were performed in 2 patients (15%) out of 8 L-L (20%). Median PFS was 7 months (3-69+ months). Median OS was 19 months (6-69+ months). KRAS wild-type compared with mutant patients did not show significantly different PFS nor OS (Figures 1(c) and 1(d) ). Table 2 , which describes rDI).
Dose-Intensity and
One patient (3.5%) discontinued FIr-B/FOx treatment due to limiting toxicity (grade 3 diarrhea). G3-4 toxicities, by patients, in 134 cycles, were (Table 3 ) diarrhea, 6 (21%); stomatitis/mucositis, 3 (11%); asthenia, 3 (11%); and neutropenia 3 (11%). The prevalent toxicity was diarrhea, G2-G3 in 14 patients (50%), similar to non-elderly [1] . G2 toxicities were nausea 11 (39%), vomiting 3 (11%), diarrhea 8 (29%), asthenia 11 (39%), neurotoxicity 4 (14%), hypertension 3 (11%), and neutropenia 11 (39%). No cases of thrombosis, hemorrhage/bleeding, cardiac or cerebrovascular ischemia, G4 neutropenia, febrile neutropenia, severe thrombocytopenia, or toxic deaths were observed. LTS were observed in 13 out of 28 young-elderly patients (46%) ( Table 4) : LTSms, 11 pts (39%) and LTS-ss, 2 pts (7%). LTS-ms were characterized by: LT associated to other, at least G2, nonlimiting toxicities, 9 pts (32%); and ≥2 LTs, 2 pts (7%). LTS were significantly represented by LTS-ms compared to LTSss (chi-square 3.832, = 0.05), with respect to non-elderly patients. LTS were (see Supplementary material, Table 3 , which describes toxicities characterizing LTS in individual patients) G2-3 diarrhea-associated, 9 patients (69.2%), 8 LTSms and 1 LTS-ss; G3 mucositis associated with G3 erythema, 1; G3 stomatitis/mucositis and G2 asthenia, 1; G2 neutropenia for >2 weeks with G2 nausea, 1; and G3 asthenia, 1. Figure 1(b) , which reports PFS and OS of KRAS mutant patients, L-L versus O/MM), not significantly different.
Activity and Efficacy according to KRAS
Discussion
First line medical treatment of MCRC patients consists of triplet regimens including chemotherapeutic drugs, or doublets plus BEV, or doublets plus EGFR-inhibitors in KRAS wild-type patients, showing ORR 39%-68%, PFS 7.2-10.6 months, and OS 19.9-26.1 months [2, 4, 7, 8] . Triplet FOLFOXIRI regimen gained ORR 60%, PFS 9.8 months, and OS 23.4 months, and recently showed 5 years-PFS 5% and 5 years-OS 15% [7] . More intensive regimens, consisting of triplet chemotherapy plus targeted agents, can further increase activity, efficacy, and effectiveness of liver metastasectomies [1, 38, 39] . Phase II studies, by Masi et al. [38] , and by our group [1] , proposed BEV addition to triplet chemotherapy, according to FOLFOXIRI/BEV or FIr-B/FOx schedules, reaching ORR 77% and 82%, liver metastasectomies 40% and 54% in L-L disease, median PFS 13.1 and 12 months, and median OS 30.9 and 28 months. Present retrospective analysis showed that youngelderly patients represented 42% of MCRC patients treated with FIr-B/FOx intensive regimen, mainly characterised by performance status 0 (89%) and intermediate CIRS (93%) stage and confirmed high activity and efficacy (ORR 79%, PFS 11 months, and OS 21 months), as reported in overall MCRC patients [1] .
Retrospective analysis of doublets CPT-11, or OXP, associated to 5-FU or capecitabine in older patients reported ORR 18-59.4%, PFS 4.9-10.0 months, and OS 8.5-20.7 months [13-20, 29, 40] . The addition of BEV to 5-FU-based chemotherapy in elderly patients significantly increased PFS 9.2-9.3 and OS 17.4-19.3 months [22, 23] . Triplet chemotherapy or doublet plus BEV obtained ORR 34.9-45.9%, PFS 7.9-9.3 months, and OS 17.4-20.5 months [23] [24] [25] . In the HORG-FOLFOXIRI trial, no different clinical outcome was observed in elderly patients; significantly lower PFS and OS were reported in patients with performance status 2 [28, 29] . Liver metastasectomies were reported in 1.3% and 4.2% patients treated with FOLFIRI and FOLFOXIRI, respectively, [29] and can achieve OS 43 months, not significantly different from younger patients [41] . Morbidity and/or mortality after liver surgery were significantly higher in elderly patients (8%) [42] . Our present retrospective data show that intensive FIr-B/FOx treatment of young-elderly MCRC patients, carefully selected according to comorbidity and functional status, may achieve increased activity and clinical outcome than that reported. The high activity is correlated with 18% liver resection rate, 37.5% in L-L patients, and 40% pathologic CR, without increased morbidity and/or mortality.
FOLFOXIRI plus BEV and FIr-B/FOx schedules may increase activity and efficacy in patients with KRAS wildtype and mutant genotypes [5, 38] . Median OS of patients treated with FIr-B/FOx was different in KRAS wild-type and mutant patients (38 months and 21 months, resp.), but not significantly different [5] . Similarly, FIr-B/FOx clinical outcome was not significantly different according to KRAS genotype, in young-elderly patients. Our previous reports of significantly different clinical outcome of L-L compared to multiple metastatic disease [3] , particularly in KRAS wildtype patients, while not in KRAS mutant [5] , were confirmed in young-elderly patients and should be prospectively verified.
FIr-B/FOx in young-elderly patients was feasible at median rDI 80%. Cumulative G3-4 toxicities were prevalently represented by diarrhea (21%), stomatitis/mucositis (11%), asthenia (11%), and neutropenia (11%). Individual LTS were reported in 46% young elderly patients, mainly including diarrhea (69.2%), and significantly more represented by LTSms compared to LTS-ss (chi-square 3.832, = 0.05), with respect to non-elderly patients. Published studies showed that grade 3/4 toxicities were not significantly different in elderly patients treated with 5-FU or CPT-11 [14] [15] [16] , slightly increased with FOLFOX [19] , and significantly increased by capecitabine (40%), while not by the addition of OXP [20] . Limiting diarrhea was significantly higher with FOLFIRI and FOLFOXIRI [28, 29] . Performance status 2 was significantly associated with increased grade 3/4 neutropenia, febrile neutropenia, diarrhea, and fatigue, compared with performance status 0-1 [28, 29, 40] . In elderly patients, BEV addition to chemotherapy was significantly associated with increased arterial thromboembolism [43] , while not to other adverse events [22] [23] [24] [25] . The present retrospective, exploratory analysis in a small cohort of MCRC patients, showed that intensive FIr-B/FOx schedule is equivalently safe and feasible, without severe adverse events related to BEV, in young-elderly patients, selected by favourable performance status and functional and comorbidity status, with a rate of LTS-ms significantly increased compared to LTS-ss, with respect to non-elderly patients. Young-elderly MCRC patients suitable for FIr-B/FOx intensive treatment should be carefully selected based on comorbidity and functional status and monitored for individual safety in clinical practice.
Conclusions
In fit young-elderly patients, FIr-B/FOx intensive regimen is safe, with toxicity characterized by LTS-ms, high activity, efficacy, and liver metastasectomies, particularly in L-L, KRAS wild-type, compared to O/MM. Present findings would be prospectively verified in a larger cohort of young-elderly MCRC patients.
